Literature DB >> 15190153

LMO2 and gene therapy for severe combined immunodeficiency.

Alain Fischer, Salima Hacein-Bey Abina, Adrian Thrasher, Christof von Kalle, Marina Cavazzana-Calvo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15190153     DOI： 10.1056/NEJM200406103502422

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

2.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 3.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

4.  Chemoprotection in brain tumor patients: another success for stem cell gene therapy.

Authors:  Brian P Sorrentino
Journal:  Mol Ther       Date:  2012-08       Impact factor: 11.454

Review 5.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 6.  New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing.

Authors:  Donald B Kohn; Caroline Y Kuo
Journal:  J Allergy Clin Immunol       Date:  2017-03       Impact factor: 10.793

7.  Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation.

Authors:  Katrin Hacke; Rustom Falahati; Linda Flebbe-Rehwaldt; Noriyuki Kasahara; Karin M L Gaensler
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 9.  Biology and clinical application of CAR T cells for B cell malignancies.

Authors:  Marco L Davila; Michel Sadelain
Journal:  Int J Hematol       Date:  2016-06-04       Impact factor: 2.490

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.